This test is most useful if any of these apply to you.
Enterococcus can become a large share of the gut community when other bacteria decline. In people receiving intensive care or donor stem cell transplants, that expansion has been associated with infections and poorer survival. Those findings make it a useful research subject, but they don't establish that a stool result can predict those outcomes in an otherwise healthy person.
Stool abundance is an exploratory marker. There is no validated healthy target for this genus, and measuring it has not been shown to improve routine preventive care. An isolated result cannot establish whether your gut has recovered from antibiotics.
Enterococcus is a genus containing several bacterial species. E. faecalis and E. faecium are familiar members, but healthy people can also carry other species. In a culture study of 51 healthy volunteers, E. lactis was the most frequently recovered species. The researchers examined 315 bacterial isolates from those volunteers, not 315 separate people.
Species and strains differ in their ability to resist antibiotics, produce toxins, and cause infection. Some strains also produce antibacterial proteins that inhibit competitors in laboratory experiments. A combined genus result groups these organisms together, so abundance alone cannot describe their behavior.
This stool measurement uses shotgun metagenomic sequencing to estimate relative abundance. The method reads microbial DNA across the sample and identifies the organisms it came from. The result describes the share assigned to Enterococcus.
A larger percentage can reflect growth of this genus, loss of other organisms, or both. Sequencing detects DNA and does not establish that every detected organism is alive. Stool also samples a different microbial community from the intestinal lining or the small intestine.
Much of the hospital research used 16S sequencing, which identifies bacteria through a particular gene. Other studies counted organisms grown in culture or collected rectal swabs. These related measurements support the biological associations described below, but their numerical results are not interchangeable with this stool sequencing result.
In a study of 301 adults entering a medical intensive care unit, researchers used rectal swabs and 16S sequencing. People whose samples were dominated by Enterococcus had a higher rate of death or infection during the following month after adjustment for measured differences, including illness severity.
The association persisted in people whose screening cultures did not detect vancomycin-resistant enterococci. This did not prove that expansion caused the events. Genus dominance also did not specifically predict subsequent enterococcal infection in that study.
A separate study of critically ill adults with COVID-19 found that higher enterococcal concentrations in rectal samples were associated with mortality. Those were counts of living organisms recovered by culture, a different measurement from the percentage of DNA assigned to this genus.
A systematic review of critical-care studies found that dominance by particular organisms was associated with mortality more consistently than broad measures of bacterial diversity. The studies differed substantially, and the evidence was too limited to turn these observations into a reliable individual prognosis.
Among donor stem cell transplant recipients studied across four centers, Enterococcus dominance in stool sequencing was associated with lower survival and more deaths related to graft-versus-host disease. This condition occurs when donor immune cells attack your tissues. The human findings were observational; accompanying mouse experiments provided evidence that particular enterococcal expansions could worsen disease in that experimental setting.
In a study of people with acute necrotizing pancreatitis, Enterococcus expansion detected by rectal-swab sequencing often appeared before infection of damaged pancreatic tissue. The expansion was associated with a severalfold higher rate of subsequent infected necrosis after adjustment for several clinical factors. The estimate came from a small, severely ill population and does not provide a risk estimate for someone taking a preventive stool test.
The intestine can be a reservoir for enterococcal infection. Genomic studies in hospitalized people have matched gut-colonizing strains with strains later recovered from the bloodstream. They have also documented acquisition and transmission of strains within hospitals.
Studies comparing stool and urine isolates have found genetically related E. faecalis strains in some people with urinary tract infections. That supports the gut as a possible source, but a urinary infection does not necessarily involve bacteria crossing the intestinal wall. A stool abundance result cannot establish the source of an infection or predict that one will occur.
In a prospective hospital study, people who subsequently developed Clostridioides difficile infection had more Enterococcus in their baseline stool profiles before antibiotic treatment. Research in hospital-acquired diarrhea has also linked enterococcal expansion to changes in stool chemistry.
These findings do not establish that Enterococcus causes C. difficile infection. The reported changes in tyrosine and tyramine do not prove that this chemical conversion makes C. difficile spores germinate in people. Genus abundance is not a substitute for testing for C. difficile when symptoms suggest that infection.
Small studies have reported increased fecal Enterococcus in inflammatory bowel disease and ischemic colitis, alongside changes in other bacteria. The findings vary between populations and do not establish that this genus caused the inflammation.
There are plausible mechanisms, but much of that evidence comes from experiments. Certain E. faecalis strains produce reactive chemicals that damage DNA in cultured cells. Experiments using cultured intestinal cells and mouse tissue have also shown that the bacterial enzyme gelatinase can increase intestinal permeability. These findings concern particular strains and experimental conditions; a genus-level stool result does not show that these processes are happening in your bowel.
A study of colorectal cancer found more Enterococcus DNA in tumor tissue than in nearby non-tumor tissue from the same people. Tissue measurements are different from stool measurements. That association does not validate fecal Enterococcus as a colorectal cancer screening test.
In advanced cirrhosis, Enterococcus-rich stool communities have been associated with antibiotic exposure, markers of impaired intestinal barrier function, and inflammation elsewhere in the body. These factors occur together in serious liver disease, making it difficult to separate cause from consequence.
In hepatitis B-related acute-on-chronic liver failure, one study found higher E. faecium abundance in people whose condition progressed. This was a species-specific finding, so it cannot be treated as an equivalent finding for the total genus.
In primary sclerosing cholangitis, researchers associated greater fecal Enterococcus abundance with shorter transplant-free survival. They separately associated detection of cytolysin genes with poorer survival. Cytolysin is a toxin produced by some strains. Detecting its genes is a different measurement from total genus abundance, and this result does not establish whether those genes are present.
A small liver-cancer study used Enterococcus alongside other microbial features to distinguish advanced from earlier disease. The reported model performance belonged to a combination of bacterial measurements, not to this genus alone. This remains exploratory classification research and does not establish a screening or staging use for your stool result.
Evidence-backed interventions that affect your Enterococcus level
Enterococcus is best interpreted alongside these tests.
Enterococcus is included in these pre-built panels.
See what your gut microbes are actually doing, not just whether your digestion feels off, and track the balance over time.